Terumo Bundle
How has the Terumo Company shaped the medical landscape?
Terumo Corporation, a name synonymous with medical innovation, boasts a fascinating history that began over a century ago. Founded in 1921 as the Red Line Thermometer Corporation, Terumo's journey started with a commitment to producing reliable clinical thermometers in Japan. This dedication to precision and quality set the stage for Terumo's evolution into a global leader in the healthcare industry.
From its origins as a Terumo SWOT Analysis manufacturer, Terumo Corporation has consistently expanded its product portfolio. Today, the Japanese company offers a diverse range of medical devices, including vascular intervention solutions and blood transfusion technologies. This brief overview of Terumo highlights its significant contributions to healthcare and its enduring impact on medical technology, showcasing its impressive growth over time.
What is the Terumo Founding Story?
The Terumo Company, a significant player in the medical device industry, has a rich history rooted in Japan. The story of Terumo Corporation begins with a vision to address a critical need in healthcare. This Japanese company's origins are a testament to its commitment to innovation and public health.
Terumo's journey started on September 17, 1921, when it was established as the Red Line Thermometer Corporation. This marked the beginning of a long and impactful presence in the healthcare industry. The founders, a team of medical scientists led by Dr. Shibasaburo Kitasato, aimed to manufacture reliable clinical thermometers domestically.
The founding of Terumo Corporation was driven by the scarcity of accurate thermometers in Japan. The company's initial focus was on producing and distributing these essential medical devices. Terumo's early products, like the 'Jintan Taionkei' launched in February 1922, quickly gained recognition for their quality. The company's name evolved over time, from Jintan Thermometer Corporation in 1936 to Terumo Corporation in 1974, reflecting its expanding scope and impact.
Key Highlights of Terumo's Founding
Terumo Corporation's founding was a response to the need for reliable medical instruments in Japan.
- Founded on September 17, 1921, as the Red Line Thermometer Corporation.
- Led by Dr. Shibasaburo Kitasato, a prominent medical scientist.
- Initially focused on manufacturing clinical thermometers.
- Launched its first product, the 'Jintan Taionkei,' in February 1922.
- Name evolved from Jintan Thermometer Corporation to Terumo Corporation in 1974.
Terumo SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Terumo?
The early growth and expansion of the Terumo Company were marked by strategic diversification and a strong push into disposable medical devices. This phase saw the company evolve from its initial focus on thermometers to a broader range of healthcare products. The
Product Diversification
A significant milestone was the launch of Japan's first disposable syringes in 1963, addressing infection concerns. This was followed by Japan's first disposable hypodermic needles in 1964. In 1969, Terumo introduced Japan's first blood bag containing a blood preservative. These early products highlight
International Expansion
International expansion began in 1971 with Terumo America Inc. in the U.S. and Terumo Europe S.A. in Belgium. This marked the company's ambition to become a global player. The company's global expansion continued with the establishment of manufacturing facilities worldwide.
Product Innovation
In 1973, Japan's first intravenous solutions in soft plastic bags were launched. The company entered the artificial organs field with a hollow-fiber dialyzer in 1977. In 1982, the world's first microporous hollow-fiber membrane oxygenator, the CAPIOX II, was launched.
Corporate Development
The company officially changed its name to
Terumo PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Terumo history?
The Terumo Company, a prominent player in the healthcare industry, has a rich history marked by significant milestones. These achievements showcase its evolution from a Japanese company to a global medical device company.
| Year | Milestone |
|---|---|
| 1982 | Introduced Japan's first insulin syringe with a fixed needle and a digital thermometer for hospital use, discontinuing mercury thermometer production in 1984. |
| 1982 | Launched the CAPIOX II, the world's first microporous hollow-fiber membrane oxygenator, establishing itself as a major innovator in artificial organs. |
| 1985 | Entered the field of cardiovascular intervention therapies with the Japanese launch of an angiographic catheter system. |
| 1999 | Acquired the cardiovascular division of 3M Company, establishing Terumo Cardiovascular Systems Corp. in the USA, strengthening its position in the cardiovascular products market. |
| 2002 | Acquired Vascutek, expanding its reach into vascular grafts. |
| 2006 | Acquired MicroVention Inc., expanding its reach into neuroendovascular devices. |
| 2011 | Acquired CaridianBCT, leading to the formation of Terumo BCT and a significant expansion in blood management and cell therapy technologies. |
Throughout its history, the
Microporous Hollow-Fiber Membrane Oxygenator
In 1982, the launch of the CAPIOX II marked a significant innovation, positioning Terumo as a key player in artificial organs. This technology revolutionized the field of extracorporeal circulation.
Angiographic Catheter System
The introduction of the angiographic catheter system in 1985 expanded the company's presence in cardiovascular intervention therapies. This system improved the precision and safety of diagnostic and interventional procedures.
Insulin Syringe and Digital Thermometer
Terumo's introduction of Japan's first insulin syringe with a fixed needle and a digital thermometer in the early 1980s showcased its commitment to patient safety and technological advancement. These products replaced less safe or less efficient alternatives.
Quantum Flex Cell Expansion System
The Quantum Flex Cell Expansion System, developed through the acquisition of CaridianBCT, demonstrated rapid CAR-T cell expansion for therapeutic doses by February 2024. This innovation supports advanced blood therapies and cell therapy technologies.
Vascular Grafts
The acquisition of Vascutek expanded its reach into vascular grafts, providing advanced solutions for vascular diseases. These grafts are crucial for treating various cardiovascular conditions.
Neuroendovascular Devices
Acquiring MicroVention Inc. allowed Terumo to expand its portfolio with neuroendovascular devices. These devices are essential for treating conditions like aneurysms and strokes.
The
Market Downturns
The company has had to navigate economic fluctuations and shifts in healthcare spending. These challenges require adaptability and strategic financial planning.
Evolving Healthcare Landscapes
Changes in healthcare regulations, technological advancements, and patient needs have required continuous adaptation. The company must stay at the forefront of innovation to remain competitive.
Customer-Centric Approach
Terumo's shift from a product-centered to a customer-centered approach, as outlined in its 5-Year Growth Strategy (GS26) starting in April 2022, aims to create valuable solutions with medical professionals and partners. This strategy is essential for meeting evolving customer needs.
CDMO Expansion
The company's strategic move into the Contract Development and Manufacturing Organization (CDMO) space, targeting the biopharma sector, which is projected to exceed $160 billion by 2030, represents a significant opportunity. This expansion involves substantial investments, such as the planned 15 billion yen expansion of pre-filled syringe production facilities at Terumo Yamaguchi Corporation Ltd., increasing capacity by 3.5 times compared to 2016.
Strategic Acquisitions
Acquisitions like the cardiovascular division of 3M Company, Vascutek, MicroVention Inc., and CaridianBCT have been crucial for expanding its product portfolio and market reach. These moves have strengthened its position in key healthcare segments.
Diversification and Innovation
The company's focus on innovation and diversification, including its expansion into CDMO services, has allowed it to overcome challenges and maintain its leadership in the medical device industry. This approach ensures long-term growth and resilience.
Terumo Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Terumo?
The Terumo Company, a significant player in the healthcare industry, has a rich history marked by innovation and strategic expansion. Founded in 1921 by Dr. Shibasaburo Kitasato, the Japanese company began as Red Line Thermometer Corporation and has since grown into a global medical device company. Over the years, Terumo has consistently introduced groundbreaking products, expanded its global presence, and adapted to the evolving needs of the healthcare sector. This commitment to innovation has solidified its position in the market.
| Year | Key Event |
|---|---|
| 1921 | Founded as Red Line Thermometer Corporation in Japan by Dr. Shibasaburo Kitasato. |
| 1922 | Launched 'Jintan Taionkei,' the company's first clinical thermometer. |
| 1936 | Company name changed to Jintan Thermometer Corporation. |
| 1963 | Launched Japan's first disposable syringes. |
| 1969 | Launched Japan's first blood bag containing a blood preservative. |
| 1971 | Established Terumo America Inc. (U.S.) and Terumo Europe S.A. (Belgium). |
| 1974 | Company name changed to Terumo Corporation. |
| 1977 | Entered the artificial organ field with the launch of a hollow-fiber dialyzer. |
| 1982 | Launched the world's first microporous hollow-fiber membrane oxygenator (CAPIOX II). |
| 1985 | Launched angiographic catheter system in Japan, entering vascular intervention. |
| 1999 | Acquired 3M Company's cardiovascular division, forming Terumo Cardiovascular Systems Corp. |
| 2002 | Acquired Vascutek Ltd., a UK manufacturer of vascular grafts. |
| 2006 | Acquired MicroVention Inc., expanding into neuroendovascular devices. |
| 2011 | Acquired CaridianBCT, significantly expanding blood management and cell therapy. |
| 2018 | Vascutek and Bolton Medical merged to form Terumo Aortic. |
| 2021 | Celebrated 100th anniversary. |
| 2022 (April) | Began 5-Year Growth Strategy (GS26) with vision 'From Devices to Solutions.' |
| 2024 (November) | Announced plans to invest USD 15 million in China by 2025 for localized manufacturing and business expansion. |
| 2025 (January) | Launched the Terumo Injection Filter Needle. |
| 2025 (February) | Partnered with Daiichi Sankyo Vietnam to enhance cardiovascular expertise in Vietnam. |
| 2025 (May) | Entered an agreement to purchase WuXi Biologics' drug product plant in Leverkusen, Germany, for EUR 150 million. |
| 2025 (May) | Announced early commercial availability of the FDA-approved ROADSAVER™ Carotid Stent System. |
Financial Performance and Projections
For the fiscal year ending March 31, 2025 (FY2024), Terumo's sales revenue exceeded 1 trillion yen, reaching 1,036.2 billion yen, a 12% increase over the previous year. Operating profit reached a record high of 157.7 billion yen despite one-time expenses of 24.2 billion yen. Looking ahead to FY2025, Terumo anticipates continued global growth.
Strategic Initiatives
Guided by its 5-Year Growth Strategy (GS26), Terumo aims for a high-single-digit revenue annual growth rate and an operating margin of over 20% by 2026. The company is expanding its Contract Development and Manufacturing Organization (CDMO) services. Geographic expansion into high-growth regions is also a key focus.
Future Growth Drivers
Terumo is progressing with its source plasma collection system rollout in the US and continues to invest in new growth areas and IT, including core systems like SAP. Analyst predictions suggest a compounded annual revenue growth rate of 7.2% for Terumo in the next five years, driven primarily by overseas sales and new product launches.
Vision and Values
Terumo's future outlook remains tied to its founding vision of 'Contributing to Society through Healthcare.' The company strives to be of value to patients, medical professionals, and society at large through continuous innovation and strategic growth. This commitment underpins its long-term strategy.
Terumo Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What is Competitive Landscape of Terumo Company?
- What is Growth Strategy and Future Prospects of Terumo Company?
- How Does Terumo Company Work?
- What is Sales and Marketing Strategy of Terumo Company?
- What is Brief History of Terumo Company?
- Who Owns Terumo Company?
- What is Customer Demographics and Target Market of Terumo Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.